China Pharmaceutical University;
Nanjing;
China;
School of International Pharmaceutical Business;
China Pharmaceutical University;
Nanjing;
China;
Atezolizumab; Non-Small Cell Lung Cancer; Partitioned Survival Model; Cost-Effectiveness Analysis;